September 20, 2018 EBPA Program
NOTE: No Insurance Credits this month**
Event sponsored by
Evidence for a new category of diabetes care: Reversal
Introduction to Virta Health
- First treatment proven to reverse type 2 diabetes without surgery or medication.
- Medically supervised
- National reach
- 12-month initial treatment
- Remote & continuous interaction
- Outcomes-based fees
Diabetes reversal context
- Standard of care outcomes
- diabetes care landscape
- definition of
- High-level outcomes (CVD risk, A1c, medication, and inflammation)
- enrollee demographics
- background on study design
- average outcomes (weight, a1c, reversal, cost savings)
- Outcomes vs control arm
- Technology stack
- Nutritional protocol
- Care team interactions
- Comprehensive behavioral change in related areas
- Cost savings in detail
- Drivers of cost savings
- Fee structure
Virta Health delivers the first clinically-proven treatment to safely and sustainably reverse type 2 diabetes and other chronic metabolic disease without the risks, costs, or side effects of medications or surgery. Join us for this educational session as we review the impact of the Virta Treatment on metabolic and cardiovascular health in our clinical trial and nationwide commercial populations. We’ll discuss how nutritional ketosis combined with continuous remote care—technology-enabled and proactive, near real-time care from physicians and health coaches—is helping patients normalize blood sugar, remove diabetes medications, and lose clinically-significant body weight.
Empowering People with Chronic Conditions to Live Better Lives
Current approach to chronic condition management isn’t working
- Health status of US population with diabetes and pre-diabetes
- Cost of diabetes and pre-diabetes in the US
Review of Research Studies Demonstrating Clinical and Financial Outcomes related to well-managed diabetes
- Art & Science of Diabetes Self-Management Education - AADE 7 Self-care behaviors
- decreased clinical complications (DCCT, UKPDS, DPP)
- decreased medical spending (Gilmer 1997, 2005; Fitch 2003)
The Livongo Solution
- Clinical Outcomes
- Cost savings
Livongo has a vision of empowering all people with chronic conditions to live better and healthier lives. We are redesigning chronic condition management--starting with diabetes, and now hypertension--by driving behavior change through the combination of consumer health technology, personalized recommendations, and real-time support at the point of impact. Powered by advanced analytics, we create personalized experiences for our members so they receive the right information, tools, and support, at the right time. Our approach is leading to better financial and clinical outcomes while creating a better experience for all people with chronic conditions and their care team of family, friends, and medical professionals.
Dr. James McCarter is Head of Research for San Francisco-based Virta Health, a tech-enabled nationwide medical provider that delivers the first clinically-proven treatment to safely and sustainably reverse type 2 diabetes without medications or surgery. He is also an Adjunct Professor of Genetics at Washington University (WU) School of Medicine in St. Louis and an Entrepreneur in Residence at the venture fund BioGenerator. Previously, Dr. McCarter was the Founder, President, and Chief Scientific Officer of Divergence, Inc., a frontrunner in the application of genomics to infectious disease and agriculture. The Company’s numerous discoveries led to products in veterinary therapeutics and diagnostics and agrochemistry. He is an author of over 60 scientific publications and patents. Dr. McCarter is a recipient of the Innovation Award from the Academy of Science of St. Louis and a Crown Fellow of the Aspen Institute.
Jenna Bollyky, MD is a Stanford physician who leads Livongo’s clinical research and analytics. Jenna’s background includes undergraduate degree in Economics (Princeton, 1995), MD/MBA from UCLA (2000), clinical training in internal medicine (Brigham and Women’s Hospital, 2001-2004), endocrinology and bioinformatics (Stanford University, 2013-2015). Her research over the years has focused on various aspects of diabetes innovation including phase I/II clinical investigations of immunotherapies to preserve beta cell function and artificial pancreas technologies for type 1 diabetes (Benaroya Research Institute at Virginia Mason, Seattle) and health outcomes (NIDDK, RAND). Jenna currently lives on Stanford campus with her husband, Paul, and their three children. In addition to being a provider and researcher, Jenna is a patient who has been living with type 1 diabetes for over 30 years.
- 7:15-8:00 am Registration, Breakfast, WAOIC sign in
- 8:00-8:50 am Program
- 8:50-9:00 am Break
- 9:00-9:50 am Program
- 9:50-10:00 am Q&A, WAOIC sign out
$65 members; $85 non-members and guests by registration deadline.
$80 members; $100 non-members and guests after deadline or at door.
NO INSURANCE CREDITS OFFERED FOR THIS MONTH'S PROGRAM.
Due to required application process with the Office of the Insurance Commissioner, filing for CE credit was not able to be completed. EBPA strives to bring the best curriculum to you, and although we view CE credits as valuable, we know the knowledge gained is most important.